PPIs Found to Ameliorate Postnasal Drainage Symptoms
Eight weeks of proton pump inhibitor therapy improved symptoms by 50 percent
TUESDAY, Dec. 21 (HealthDay News) -- Symptoms associated with chronic postnasal drainage are improved by lansoprazole, according to a study published in the December issue of Gastroenterology.
Michael F. Vaezi, M.D., Ph.D., of the Vanderbilt University Medical Center in Nashville, Tenn., and colleagues performed a four-month, randomized, controlled, placebo-based trial to investigate whether acid suppression improves symptoms of postnasal drainage. Seventy-five patients with chronic postnasal drainage were randomly assigned to receive either lansoprazole 30 mg twice-daily or a placebo. Patients were assessed for reflux symptoms at the beginning of the study, and impedance pH was monitored on 65 percent of the participants. Data were gathered at the two- and four-month point by assessments and questionnaires.
The investigators found a significant improvement in the reported postnasal symptoms of those using lansoprazole. After two months, patients on lansoprazole were 3.12 times more likely to see an improvement than those taking a placebo. By four months, the likelihood of the study group seeing an improvement grew 3.5-fold. Those taking lansoprazole reported a median 50 percent improvement in their symptoms at four months, compared to a 5 percent improvement reported by the placebo group. The investigators did not find that reflux symptoms predicted who benefited from the therapy.
"We have found that, among patients with chronic postnasal drainage without evidence of sinusitis and allergies, twice-daily proton pump inhibitor therapy resulted in significant improvement at eight and 16 weeks. There was no evidence that presence of typical symptoms, heartburn or regurgitation, or abnormal esophageal acid, acid or nonacid exposure, modified response to therapy," the authors write.
Takeda Pharmaceuticals provided funding for the study coordinator, patient compensation, and samples of lansoprazole and an identical-appearing placebo.